BCI funding: a quarter-by-quarter analysis

All funding deals in the brain-computer interface market over the last years

Below is the table listing all the deals. You can find our methodology at the end of this page.

If you want a deeper understanding of the market and its current dynamics, get our report on neurotech funding, valuations and who's ahead.

Is brain-computer interface funding actually growing every quarter?

Brain-computer interface funding is growing consistently in the number of deals, but the amount of money invested still swings wildly from one quarter to the next.

We counted 57 BCI financings between Q2 2025 and Q3 2026. Quarterly deal activity increased from nine in Q1 2026 to fifteen in Q2 and seventeen in Q3. That is almost twice as many transactions in six months.

Capital tells a different story. Investment reached $698.1 million in Q1 2026, dropped to $192.2 million in Q2, then recovered to $449.9 million in Q3. A few exceptionally large rounds explain most of those movements.

We also calculated funding excluding transactions above $50 million. On that basis, investment increased from $87.6 million in Q1 to $137.2 million in Q2 and barely changed in Q3.

The market is clearly attracting more funded startups. Investors are spreading smaller checks across a wider group of companies, while the largest financings remain unpredictable.

Quarter	Deals	Disclosed capital	Capital excluding >$50M
Q2 2025	1	$650.0M	$0
Q3 2025	5	$173.2M	$73.2M
Q4 2025	10	$333.4M	$133.4M
Q1 2026	9	$698.1M	$87.6M
Q2 2026	15	$192.2M	$137.2M
Q3 2026	17	$449.9M	$137.9M

When did BCI startup funding really start taking off?

BCI startup funding began reaching a much wider range of companies in late 2025, several months before the stronger Seed-stage expansion of 2026.

Q2 2025 was dominated by Neuralink's $650 million Series E, announced on June 2. It was the only financing recorded that quarter.

Activity increased to five deals in Q3, led by Nudge's $100 million financing. The more convincing change came in Q4, when ten companies raised money and disclosed capital reached $333.4 million.

Synchron's $200 million financing was the biggest transaction, but the remaining numerically disclosed rounds still contributed $133.4 million. That was 82% more than the comparable amount in Q3.

At the same time, the median disclosed financing declined from $35.9 million to $20 million. More companies were getting funded, including startups raising considerably less than the most established developers.

By late 2025, the market was already supporting a larger group of BCI businesses. The wave of Chinese Seed financings would make that expansion considerably more visible in 2026.

Why did BCI funding suddenly explode in Q1 2026?

The Q1 2026 BCI funding boom came mainly from BrainCo and Merge Labs, which together raised $538 million.

BrainCo secured $286 million, while Merge Labs raised $252 million. Those transactions represented roughly 77% of the quarter's $698.1 million total.

Both had reasons to attract attention beyond conventional venture financing.

BrainCo's relationship with Lens Technology involved hardware manufacturing and potential industrial scaling. Merge Labs, meanwhile, announced its launch in January 2026 with backing from OpenAI. OpenAI described a research collaboration involving neural interfaces, AI models and new ways of connecting biological and artificial intelligence.

Gestala also attracted strategic interest through its relationship with rehabilitation technology company Fourier Intelligence.

These financings were connected to different ambitions: manufacturing brain-interface hardware, developing new interface architectures and bringing neurotechnology into rehabilitation.

All three areas can require substantial research and development capital.

The size of these deals pushed the quarterly average disclosed financing to $116.4 million, compared with $47.6 million in Q4 2025. Yet the number of transactions actually declined from ten to nine.

Investors were making unusually large commitments to selected companies. For much of the wider BCI market, it was a fairly ordinary quarter in dollar terms.

Why did BCI funding collapse in Q2 2026 even though more startups raised money?

BCI funding fell 72% in Q2 2026 because the previous quarter had been inflated by enormous rounds, while investors were now financing many more early-stage companies.

Deal activity increased from nine to fifteen transactions, and the number of Seed rounds jumped from three to twelve. Twelve seed rounds in one quarter is a wide field of new startups; we follow who is getting funded, and by whom, in our report covering neurotech.

Axoft's $55 million financing was the quarter's largest. It represented 29% of disclosed capital, far below the concentration seen around BrainCo and Merge Labs one quarter earlier.

The technology mix changed too. Implantable cortical BCI financings increased from two to eight, and twelve of the fifteen deals involved Asia-Pacific companies.

Smaller financing amounts, more young companies, greater regional concentration in Asia and more activity around implantable hardware all appeared in the same quarter.

Q2 had the most widely distributed disclosed funding of the six quarters we studied. The three largest transactions represented 62% of capital, compared with 88% in Q1.

For anyone looking only at total investment, Q2 appears disastrous. Looking at the companies receiving money, we reach almost the opposite conclusion: the market had its strongest expansion in early-stage financing activity.

Did BCI funding really recover in Q3 2026?

The Q3 2026 BCI funding recovery was mostly the result of Precision Neuroscience's $250 million Series D, although startup financing activity continued to increase.

Disclosed investment rose by $257.7 million compared with Q2. Precision's financing alone was equivalent to about 97% of that net increase.

The September announcement followed meaningful clinical progress. Precision reported more than 100 patient procedures across eighteen medical institutions, while its Layer 7-T cortical-interface device had received FDA 510(k) clearance in March 2025.

That clearance applies to the specified device and intended use; it does not amount to blanket authorization for every future BCI application.

The company's financing therefore came at a more advanced point in clinical development than many of the smaller transactions appearing elsewhere in the market.

Meanwhile, quarterly deal activity reached seventeen, including new financings across implantable systems, optical and ultrasound approaches, EEG devices and decoding software.

One important caution concerns disclosed amounts. Only seven of the seventeen transactions had usable numerical funding figures. The apparent recovery in average and median round size therefore rests on a relatively small subset of deals.

Startup financing activity kept growing. The dollar recovery, though, was overwhelmingly a Precision Neuroscience story.

Are a handful of BCI companies still getting most of the investment?

A few BCI companies still capture most of the disclosed funding, and that pattern returned strongly in Q3 2026 after briefly easing.

Neuralink, Nudge and Synchron each dominated one of the first three quarters in our analysis. Later, BrainCo and Merge Labs accounted for much of the early-2026 surge.

Q2 2026 was the main exception. Smaller financings represented a larger portion of the quarterly total, and the biggest deal accounted for less than one-third of disclosed capital.

By Q3, Precision Neuroscience alone represented 56% of the total, while the top three transactions contributed approximately 80%.

This concentration reflects an enormous gap in capital needs between companies experimenting with new neural-interface technology and those developing products for clinical use at scale.

Neuralink needs to finance implant development, clinical trials, surgical systems and manufacturing. Precision is advancing its Layer 7 platform toward broader clinical and commercial use. A young software or device startup raising its first round operates on a very different budget.

Large individual financings are likely to keep distorting quarterly BCI funding totals while those differences remain.

Quarter	Largest financing	Largest deal share	Top 3 share
Q2 2025	Neuralink: $650M	100%	100%
Q3 2025	Nudge: $100M	58%	99%
Q4 2025	Synchron: $200M	60%	83%
Q1 2026	BrainCo: $286M	41%	88%
Q2 2026	Axoft: $55M	29%	62%
Q3 2026	Precision Neuroscience: $250M	56%	80%

Are BCI startups getting bigger funding rounds these days?

The typical disclosed BCI funding round is still highly unpredictable, and we have no convincing evidence that checks are getting consistently bigger.

The median financing fell from $57.8 million in Q1 2026 to $13.8 million in Q2, before jumping to $46 million in Q3.

Those changes partly reflect the different companies raising money each quarter. Q1 included exceptionally large platform financings, Q2 was dominated by Seed transactions, and Q3 combined a large Series D with many smaller or undisclosed rounds.

Reporting quality also creates problems. Several Chinese financings are described using expressions such as tens of millions of renminbi, which are too imprecise for exact statistical comparisons.

By Q3, 59% of transactions lacked usable numerical funding amounts. Larger rounds are often more likely to have publicized figures, which can bias the reported median upward.

More companies are receiving financing, but the available disclosures don't justify claiming that an average BCI startup can now raise substantially more money than before.

Is China becoming the center of BCI startup funding?

China has become the main driver of BCI deal activity in our dataset, with Asia-Pacific accounting for almost nine out of ten transactions in the latest quarter.

The regional shift happened quickly. Asia-Pacific accounted for four deals in Q4 2025, eight in Q1 2026, twelve in Q2 and fifteen in Q3. Asia-Pacific going from four deals to fifteen in four quarters shifts the balance, and we point to where the biggest opportunities are in our neurotech funding report.

This expansion coincided with a more supportive Chinese industrial policy environment.

In July 2025, China's Ministry of Industry and Information Technology and six other government bodies published measures promoting the development of the BCI industry.

The policy specifically addressed implantable interfaces, neural-signal acquisition, chips, decoding software, medical applications and manufacturing. It also encouraged the use of industrial funding mechanisms to support companies working in these areas.

The timing provides a plausible explanation for greater attention from Chinese investors, although we cannot attribute individual transactions directly to the policy.

North America remains particularly important for large financings. A single American clinical-stage company can still attract more capital than the combined disclosed amounts of numerous Asian startups.

Europe has been much less active. Two European deals appeared in Q2 2026 and one in Q3, too few to establish a comparable regional expansion.

Quarter	Asia-Pacific deals	North America deals	Europe deals
Q2 2025	0	1	0
Q3 2025	4	1	0
Q4 2025	4	6	0
Q1 2026	8	1	0
Q2 2026	12	1	2
Q3 2026	15	1	1

Are more new BCI startups getting their first funding?

First-time BCI funding has become much more common, with the number of newly financed companies increasing across three consecutive quarters.

We identified one first financing in Q4 2025, followed by four in Q1 2026, five in Q2 and six in Q3.

The increase coincided with thirteen Seed-stage financings in Q3, compared with just three in Q1.

That combination suggests investors are backing a wider generation of BCI developers, especially in China.

There are limits to what the figures reveal. A first financing in our research means we did not establish an earlier qualifying round; it does not guarantee the company had never received any external capital.

Company founding dates are also incomplete, particularly among Chinese developers. Only 47% of Q2 2026 financing records contain a reliable founding date.

Still, more BCI companies are reaching venture investors for the first time in our records, and the increase has continued for several quarters.

Are BCI investors moving away from established companies?

BCI investors are financing far more early-stage companies, while established operators still receive the biggest checks.

In Q2 2026, twelve of fifteen financings were Seed rounds. Q3 recorded thirteen Seed transactions alongside one Series B and one Series D. Twelve of fifteen deals were Seed in one quarter; we follow how much money went in, quarter by quarter, in our neurotech funding report.

Precision Neuroscience's Series D supplied more than half of Q3 disclosed capital, despite Seed financings accounting for over three-quarters of the quarter's transactions.

Follow-on rounds also remain financially important. In Q3, ten deals were classified as follow-ons, representing approximately $389 million in disclosed capital. Six first financings contributed $46.9 million.

The harder question is what happens to the younger companies next.

BCI developers need to move beyond initial prototypes, build reliable hardware or software, demonstrate safety where applicable and establish practical uses. That usually requires more time and money than an early research-stage round can provide.

Our latest quarters contain relatively few Series B and Series C financings. The expanding Seed pipeline has yet to demonstrate that it can consistently produce more mature companies, although many startups are still too young to have reached those stages.

A sustained increase in follow-on financing across a much larger group of companies would be more convincing than another quarter dominated by one established name.

Are implantable BCIs attracting the most investors right now?

Implantable cortical BCIs currently have the strongest funding momentum by number of deals, although activity cooled slightly after an exceptional Q2 2026.

We recorded two financings in Q1, eight in Q2 and five in Q3. Across the latest two quarters, thirteen transactions involved this technology category.

There are understandable reasons for investor interest.

Implantable devices can capture neural activity directly from the brain, but their development involves difficult engineering and medical challenges. Companies must work on electrodes, long-term signal quality, implantation techniques, safety and decoding software.

Neuralink's progress illustrates the technical ambition. In January 2026, the company reported 21 participants enrolled in trials worldwide, alongside work on improving signal quality, surgical procedures and practical device control.

The broader financing pipeline now includes companies pursuing different implant designs and neural-recording approaches.

Funding momentum tells us where investors are placing bets. It doesn't mean these technologies are anywhere close to widespread commercial use.

Technology category	Q2 '25	Q3 '25	Q4 '25	Q1 '26	Q2 '26	Q3 '26
Implantable cortical	1	1	1	2	8	5
EEG	0	2	4	4	2	3
Optical and ultrasound	0	1	1	2	1	4
Surface/minimally invasive	0	0	2	1	2	1
Interface hardware	0	1	1	0	2	2
Endovascular	0	0	1	0	0	0
Decoding software	0	0	0	0	0	2

Are ultrasound and optical BCIs becoming serious competitors?

Ultrasound and optical BCI technologies are attracting more funding attention, but their strongest quarter is still too recent to establish lasting momentum.

The category recorded four transactions in Q3 2026, compared with one in Q2.

Two companies accounted for the numerically disclosed capital: Gestala with $62 million and BCI-Sonics with $28 million.

These approaches are attracting interest partly because developers are exploring alternatives to conventional implanted electrode systems.

Merge Labs is another relevant example. In its January 2026 launch announcement, the company described research into molecular interfaces and ultrasound-based methods intended to interact with neural activity without inserting conventional electrodes into brain tissue.

The engineering challenges differ considerably between companies, and some approaches remain highly experimental.

EEG developers are also still attracting funding. Their deal counts moved from four in Q1 to two in Q2 and three in Q3, while BrainCo's large financing previously demonstrated the amounts available to selected non-invasive BCI businesses.

Meanwhile, dedicated decoding software appeared as a separate financing category in Q3 through Omni-Intelligence and UCANACT. UCANACT disclosed approximately $940,000, while Omni-Intelligence did not report a precise amount.

Investors are exploring a wider variety of neural-interface architectures. Implantable cortical systems still have the deeper recent financing pipeline; ultrasound, optical and standalone decoding approaches need more quarters of activity before their momentum can be judged.

Are new venture capital firms entering the BCI market?

More venture capital firms are visibly leading BCI financings, especially in the expanding Asian Seed-stage market.

In Q4 2025, five transactions disclosed lead investors, involving seven distinct lead or co-lead names. By Q2 2026, ten transactions disclosed leads and seventeen names appeared. Seven lead names in Q4 grew to seventeen by Q2, and we look at which investors are placing the biggest bets in our report on neurotech.

Q3 retained a similarly broad group, with sixteen identified leads or co-leads across thirteen transactions.

Recurring investors include Matrix Partners China, CAS Star or CASSTAR-related entities and Delian Capital, although affiliated fund names need to be reconciled before claiming that particular firms dominate the market.

Better disclosure explains some of the increase. The proportion of transactions with identified leads rose from 44% in Q1 to 76% in Q3.

Nevertheless, investors were leading a greater number of actual transactions as the number of funded companies grew.

The Q2 figures are particularly revealing: disclosed capital fell sharply, yet lead-investor visibility increased. Smaller early-stage deals were attracting a wider identifiable group of backers.

The evidence supports broader investor participation, even if we cannot yet measure precisely how many venture firms are making their first BCI investments.

Why did corporate investors suddenly become interested in BCIs?

Corporate-backed BCI financing became especially visible in Q1 2026, when several companies attracted investment connected to manufacturing, AI research or rehabilitation.

Three of nine Q1 transactions involved explicitly identified strategic participation, compared with one in the preceding quarter.

Lens Technology's involvement with BrainCo was associated with manufacturing capabilities. OpenAI's investment in Merge Labs reflected interest in research connecting neural interfaces and advanced AI. Fourier Intelligence's involvement with Gestala concerned rehabilitation technology.

These investors had different reasons to participate, but all three cases involved capabilities that could be useful beyond the financing itself.

Strategic participation subsequently declined to two recorded transactions in Q2, with none explicitly classified in Q3.

Q1 therefore looks like a concentrated period of corporate interest rather than the beginning of steady quarter-by-quarter growth. Incomplete investor disclosures also prevent us from concluding that strategic capital has left the market.

For now, conventional venture investment appears more consistently represented across the growing early-stage pipeline, while corporate participation remains selective and often tied to a specific technological or commercial relationship.

Are clinical results becoming the deciding factor in big BCI funding rounds?

Clinical progress is becoming one of the strongest explanations for why certain BCI companies can raise hundreds of millions of dollars.

Precision Neuroscience provides a recent example. Before its September 2026 financing, the company had obtained FDA clearance for its temporary cortical-interface device and developed a clinical network spanning major medical institutions.

Its announcement also described a partnership with Medtronic to integrate its technology with an established neurosurgical platform, alongside efforts to expand manufacturing capacity.

Neuralink offers another perspective. Its June 2025 financing came after initial human use and the expansion of clinical research internationally. The company's later trial updates described participants using neural interfaces to control computers and assistive devices.

These developments give investors more to evaluate than an early laboratory demonstration. They can examine clinical experience, usability, device performance, safety and the practical requirements of broader deployment.

Commercial revenue and clinical progress should still be assessed separately. A medical device can achieve an important regulatory or technical milestone without having proven that its business model works at scale.

The biggest BCI rounds increasingly favor companies able to show a credible path from research to sustained clinical or industrial operations. That path is becoming an important distinction between established developers and newly financed experimental startups.

What could stop the BCI funding boom from continuing?

The biggest risk to the BCI funding boom is that the growing number of Seed-stage companies may struggle to raise the much larger rounds needed for clinical development and commercialization.

Early research funding has become more accessible across parts of the market. The harder work comes afterward. The harder work comes after the early money, and we go through the biggest unsolved problems in our report on neurotech.

Implantable-device developers face expensive engineering, testing and clinical requirements. Non-invasive systems must demonstrate reliable performance and useful applications. Software businesses need convincing evidence that their products solve problems customers or healthcare providers will pay for.

Manufacturing can create another challenge. Building a promising neural interface in a laboratory is very different from producing reliable devices consistently and economically.

The uneven stage distribution already shows where the pressure could emerge. Recent quarters contain plenty of Seed deals but relatively few Series B and Series C transactions.

There is also a geographic question. China now accounts for most newly recorded BCI financings, while North America still produces many of the largest clinical-stage rounds. It remains uncertain how many of the newly financed Asian developers will progress into larger international or domestic follow-on rounds.

The next few quarters should reveal whether the surge in startup activity is developing into a deeper financing market.

What is the BCI funding trend actually telling us?

Brain-computer interface funding has entered a broader growth phase, with more startups getting financed and more investors participating, while large-round capital remains concentrated and unpredictable.

Across the six quarters, we found a clear progression. Neuralink dominated the starting quarter, financing activity widened during late 2025, several extraordinary platform investments drove Q1 2026, and early-stage activity expanded sharply during the following two quarters.

Three developments look particularly durable: rising deal counts, more first financings and greater Asia-Pacific participation. Implantable cortical BCI technology has also built the strongest recent pipeline.

Other changes remain less convincing. The apparent recovery in typical round sizes is weakened by incomplete disclosures. The increase in strategic investment was concentrated in one quarter. Optical and ultrasound systems have attracted more attention, but their latest acceleration still needs confirmation.

The broader market is becoming more diverse. Investors are financing different neural-interface architectures, new software approaches and companies at very different points in development.

The central question now is how many of those young businesses will make it beyond their first rounds. Continued Seed activity would sustain the number of funded startups, while a larger pool of companies raising substantial follow-on capital would show that the industry is genuinely maturing.

BCI investment is becoming more widespread. The next stage will depend on whether this expanding group of companies can turn technical progress into reliable products, clinical results and ultimately sustainable businesses.